ESR1 and breast cancer: In this cohort study of 2772 patients aged 45 years or younger with ER-positive, ERBB2-negative breast cancer and no distant metastasis within 5 years after surgery, younger age was significantly associated with worse disease-free survival, locoregional recurrence-free survival, and late distant metastasis–free survival.